NDLI: ADMET considerations for restless leg syndrome drug treatments.

Please wait, while we are loading the content...

Year: 2017 Volume: 13

Year: 2016 Volume: 12

Year: 2015 Volume: 11

Year: 2014 Volume: 10

Year: 2013 Volume: 9

Year: 2012 Volume: 8

Year: 2012 Volume: 8 Issue: 12

Year: 2012 Volume: 8 Issue: 11

Year: 2012 Volume: 8 Issue: 10

Ontogeny of oral drug absorption processes in children.

ADMET considerations for phosphodiesterase-5 inhibitors.

Current toxicological aspects on drug and chemical transport and metabolism across the human placental barrier.

Ocular toxicity from systemically administered xenobiotics.

ADMET considerations for restless leg syndrome drug treatments.

Effect of cyclosporine A on hepatic carbohydrate metabolism and hepatic gene expression in rat.

Review of ticagrelor in the management of acute coronary syndromes.

An evaluation of sirolimus in renal transplantation.

Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.

Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation.

Year: 2012 Volume: 8 Issue: 9

Year: 2012 Volume: 8 Issue: 8

Year: 2012 Volume: 8 Issue: 7

Year: 2012 Volume: 8 Issue: 6

Year: 2012 Volume: 8 Issue: 5

Year: 2012 Volume: 8 Issue: 4

Year: 2012 Volume: 8 Issue: 3

Year: 2012 Volume: 8 Issue: 2

Year: 2012 Volume: 8 Issue: 1

Year: 2011 Volume: 7

Year: 2010 Volume: 6

Year: 2009 Volume: 5

Year: 2008 Volume: 4

Year: 2007 Volume: 3

Year: 2006 Volume: 2

ADMET considerations for restless leg syndrome drug treatments.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	de Biase, Stefano Merlino, Giovanni Lorenzut, Simone Valente, Mariarosaria Gigli, Gian Luigi
Description	Country affiliation: Italy Author Affiliation: de Biase S ( Department of Neurosciences, Santa Maria della Misericordia University Hospital, Udine, Italy.)
Abstract	INTRODUCTION: Restless legs syndrome (RLS) is a common neurological disorder that might impair nocturnal rest causing decreased alertness, depressed mood, reduced job performance, and poor quality of life. In patients affected by severe RLS, a pharmacological treatment is mandatory. AREAS COVERED: The present review is based on a search using PubMed from 1994 to 2012. It is focused on the Absorption, Distribution, Metabolism, Elimination and Toxicology (ADMET) characteristics of the most used medications for RLS. In particular, the ADMET characteristics of dopaminergic agents, anticonvulsants able to improve neuropathic pain, and iron were discussed. EXPERT OPINION: Clinical trials have showed that non-ergolic dopamine agonists are efficacious and safe for patients affected by moderate to severe idiopathic RLS. However, no head-to-head study has compared the long-term effects of the three dopamine agonists approved by the FDA for RLS (ropinirole, pramipexole, and rotigotine). Moreover, further studies should investigate the extended-release formulation of ropinirole and pramipexole in RLS patients affected by all day long distressing symptoms. A standardized treatment for symptomatic forms of RLS is lacking. Randomized, placebo-controlled trials should be performed at least in RLS patients with peripheral neuropathic and chronic kidney disease. Concerning RLS due to iron deficiency, a head-to-head study comparing efficacy, safety and compliance of oral iron versus intravenous one seems to be needed.
File Format	HTM / HTML
ISSN	17425255
Issue Number	10
Volume Number	8
e-ISSN	17447607
Journal	Expert Opinion on Drug Metabolism & Toxicology
Language	English
Publisher	Taylor & Francis
Publisher Date	2012-10-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Analytical Chemistry Discipline Pharmacology Benzothiazoles Therapeutic Use Dopamine Agents Indoles Restless Legs Syndrome Drug Therapy Tetrahydronaphthalenes Thiophenes Amines Adverse Effects Pharmacokinetics Anticonvulsants Carbamates Cyclohexanecarboxylic Acids Dopamine Agonists Ergolines Humans Levodopa Neuralgia Physiopathology Pregabalin Randomized Controlled Trials As Topic Treatment Outcome Gamma-aminobutyric Acid Analogs & Derivatives Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Medicine Toxicology Pharmacology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in